Video

Dr. Sklavenitis-Pistofidis on Single-Cell Dissection of Immune Cells in Smoldering Myeloma

Romanos Sklavenitis-Pistofidis, MD, discusses single-cell dissection of bone marrow and peripheral blood immune cells in smoldering multiple myeloma.

Romanos Sklavenitis-Pistofidis, MD, postdoctoral fellow, Michele and Steven Kirsch Laboratory, Dana-Farber Cancer Institute, discusses single-cell dissection of bone marrow and peripheral blood immune cells in smoldering multiple myeloma.

Researchers used single-cell dissection of bone marrow and peripheral blood immune cells in a large cohort of patients with smoldering multiple myeloma to examine changes at diagnosis and post-therapy.

Findings presented at the 19th International Myeloma Society Annual Meeting showed that significant changes were detected in the immune-cell composition of patients with smoldering multiple myeloma compared with healthy donors, Sklavenitis-Pistofidis says. Increases were observed in CD4-positive T cells, granzyme B–expressing cytotoxic T cells, and CD56dim natural killer cells. Additionally, decreases were seen in plasmacytoid dendritic cells and CD14-positive monocytes, Sklavenitis-Pistofidis explains.

Notably, patients with immune-cell composition most similar to that of healthy donors had worse outcomes, and patients who were less normal at baseline achieved significantly longer progression-free survival (PFS), Sklavenitis-Pistofidis continues. This condition has been coined immune reactivity, Sklavenitis-Pistofidis adds.

Moreover, a normalization score created by investigators increased on average between baseline and end of treatment throughout 2 years of therapy, Sklavenitis-Pistofidis says. The normalization score can be used to classify patients into those who achieved post-therapy immune normalization and those who did not, Sklavenitis-Pistofidis explains. Patients who achieved post-therapy immune normalization had significantly longer PFS, Sklavenitis-Pistofidis concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center